Pen Needles Market

7500+ companies worldwide approach us every year for their revenue growth initiatives

Global top 2000 strategist rely on us for their growth strategies.

80% of fortune 2000 companies rely on our research to identify new revenue sources.

30000 High Growth Opportunities

95% renewal rate

KNOW MORE

Pen Needles Market by Type (Standard Pen Needles, Safety Pen Needles), Length (4mm, 5mm, 6mm, 8mm, 10mm, 12mm), Therapy (Insulin, GLP 1, Growth Hormone), and Mode of Purchase (Retail, Non-Retail) - Global Forecast to 2026

FREE BROCHURE FREE SAMPLE REPORT

Report Code: MD 2851 Jun, 2021, by marketsandmarkets.com

Updated on : June 18, 2023

The global pen needles market in terms of revenue was estimated to be worth $1.3 billion in 2021 and is poised to reach $2.2 billion by 2026, growing at a CAGR of 11.2% from 2021 to 2026. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth in the market is largely driven by the growing prevalence of chronic diseases and the favorable reimbursement scenario in selected countries. On the other hand, the preference for alternative modes of drug delivery, poor reimbursement in developing countries, and needle anxiety are expected to restrain the overall market growth. The misuse of insulin pens and the reuse of pen needles are the challenges faced by the market. The growing preference for biosimilar drugs and emerging markets are areas of opportunity in the market.

Pen Needles Market

To know about the assumptions considered for the study, Request for Free Sample Report

Pen Needles Market Dynamics

Driver: Growing prevalence of chronic diseases

The prevalence of chronic diseases has increased significantly in the last few years. Such diseases-including diabetes, osteoporosis, cardiovascular disease (CVD), and multiple sclerosis-require daily or weekly drug administration, typically using pen injectors. In the rapidly growing market, pen injectors have become the new standard for injectable drug delivery systems. Their popularity has soared due to their simplicity, reliability, and ability to be administered directly by the patient without the aid of a physician. The pen needle, a removable attachment, forms an integral part of the pen injector. The length of the needle and its sharpness is critical to ensure that the medication reaches the target tissues. Thus, the growing prevalence of chronic diseases has led to a greater focus on pen needle technologies to effectively handle the growing patient pool and increase patient compliance with therapies.

Restraints: Preference for alternative modes of drug delivery

While pen needles are an easy, hassle-free mode of drug delivery, they are also associated with needlestick injuries and infections, hyperglycemia, and pain. Insulin pen therapy is seen to cause hyperglycemia in some patients, as the dose cannot be regulated. Hence, in Europe, there has been a shift in diabetes treatment, from insulin pens to insulin pumps, due to their ability to perform automated insulin suspension and decrease the risk of hypoglycemia. This is a major factor restricting market growth. Although needle-free drug delivery technologies have addressed this issue to an extent, their range of applications in therapeutic areas is limited.

Opportunity: Growing preference for biosimilar drugs

Biosimilars were introduced in 2006 by many pharmaceutical companies such as Sandoz (Germany), Teva Pharmaceutical Industries Ltd. (Israel), and JCR Pharmaceuticals Co., Ltd. (Japan). Due to their lower costs (compared to their patented counterparts), the demand for biosimilars has increased significantly. In addition, the impending patent expiry of many biologic molecules will also serve to drive the demand for biosimilars.

Even insurance companies and governments are favoring the use of biosimilars and generics. For instance, CVS Caremark, a major prescription insurer in the US, has replaced branded injectable drugs such as Lantus by Sanofi and EpiPen by Mylan with their biosimilars Basaglar (available in injection pen) by Eli Lilly and Adrenaclick (an autoinjector) by Amedra Pharmaceuticals. This favors the pen needles market as Basaglar is administered via pen injector. Many other injectable drugs also rely on pen injection; thus, the growing preference for biosimilar drugs and support from governments and insurance providers will ensure strong opportunities for growth in this market.

Challenge: Reuse in pen needles

Needle reuse is a common practice in several parts of the world, with the extent of reuse of pen needles varying across geographies from as low as 30% to a staggering 95% of patients reusing their needles. According to a study published in Value Health Journal, about 98.35% of patients reuse insulin pen needles in China.

The most common reasons for this are unaffordability, lack of or no reimbursements in many developing countries, and convenience. The reuse of pen needles is a leading factor challenging market growth, as this curtails the demand for new needles. Furthermore, a study conducted by the Moscow Regional Research Clinical Institute found that bacteria were present on pen needles post-use and that bacterial growth on needles increased with further reuse. Reusing a pen needle can lead to multiple complications such as poor glycemic control, infection, and lipohypertrophy, indicating safety concerns tied to needle reuse.

Pen Needles Market by Region

North America is expected to account for the largest share of the pen needles industry.

North America dominated the pen needles market. The growing diabetes prevalence and favorable reimbursement scenario for pen needles, federal initiatives to create awareness about injection techniques, increasing market penetration by leading players, and the development of improved pen needle technologies are driving market growth in the US.

Prominent players in the pen needles market include Becton, Dickinson and Company (US), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), B. Braun Melsungen AG (Germany), Owen Mumford (UK), Terumo Corporation (Japan), Nipro Corporation (Japan) Allison Medical (US), AdvaCare Pharma (US), Berpu Medical Technology (China), ARKRAY (Japan), GlucoRx (UK), HTL-STREFA (Poland), UltiMed, (US), Hindustan Syringes and Medical Devices (India), Artsana Group (Italy), PromiseMed Diabetes Care (Canada), Montmed (Canada), Trividia Health (US), VOGT Medical Vertrieb (Germany), Van Heek Medical (Netherlands), Simple Diagnostics (US), Iyon (Turkey), Links Medical Products (US), and MHC Medical Products (US).

Scope of the Pen Needles Industry

Report Metric	Details
Market Revenue in 2021	$1.3 billion
Projected Revenue by 2026	$2.2 billion
Revenue Rate	Poised to Grow at a CAGR of 11.2%
Market Driver	Growing prevalence of chronic diseases
Market Opportunity	Growing preference for biosimilar drugs

This research report categorizes the pen needles market to forecast revenue and analyze trends in each of the following submarkets:

By Product Type

Standard pen needles
Safety pen needles

By Length

4mm
5mm
6mm
8mm
10mm
12mm

By Therapy

Insulin therapy
Glucagon-like Peptide-1 (GLP-1) therapy
Growth hormone therapy
Other therapies

By Mode of Purchase

North America
- US
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Japan Australia and New Zealand
- South Korea
- South East Asia
- Rest of APAC
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa

Recent Developments of Pen Needles Industry

In February 2021, Ulticare safety pen needles are launched in two sizes, 5mm 30G and 8mm 30 G launched by UltiMed Inc. (US).
In October 2020, Arkray Inc. (Japan) launched TechLITE Pen Needles which are now indicated for use with pen injector devices for the subcutaneous injection of drugs in the US.
In January 2019, Becton, Dickinson and Company (US) launched Second Generation Standard Pen Needles.
In August 2018, Arkray Inc. (Japan) launched Assure ID safety pen needles.

Frequently Asked Questions (FAQ):

What is the projected market revenue value of the global pen needles market?

The global pen needles market boasts a total revenue value of $2.2 billion by 2026.

What is the estimated growth rate (CAGR) of the global pen needles market?

The global pen needles market has an estimated compound annual growth rate (CAGR) of 11.2% and a revenue size in the region of $1.3 billion in 2021.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 27)
    1.1 OBJECTIVES OF THE STUDY
    1.2 PEN NEEDLES INDUSTRY DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
           1.2.2 MARKET SEGMENTATION
           1.2.3 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
           1.3.1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
    1.4 LIMITATIONS
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 32)
    2.1 RESEARCH DATA
           FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 2 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                               FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
                               FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (PEN NEEDLES MARKET)
    2.2 MARKET SIZE ESTIMATION
           FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
           FIGURE 6 REVENUE SHARE ANALYSIS ILLUSTRATION: BECTON, DICKINSON AND COMPANY (2020)
           FIGURE 7 REVENUE ANALYSIS OF THE TOP FIVE COMPANIES: MARKET (2020)
           FIGURE 8 DEMAND-SIDE ANALYSIS
           FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           FIGURE 10 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MARKET (2021–2026)
           FIGURE 11 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN & DATA TRIANGULATION
           FIGURE 12 MARKET DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ANALYSIS
    2.5 ASSUMPTIONS FOR THE STUDY
    2.6 RISK ASSESSMENT
           TABLE 1 RISK ASSESSMENT: MARKET

3 EXECUTIVE SUMMARY (Page No. - 45)
    FIGURE 13 PEN NEEDLES INDUSTRY, BY TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 14 MARKET, BY LENGTH, 2021 VS. 2026 (USD MILLION)
    FIGURE 15 MARKET, BY THERAPY, 2021 VS. 2026 (USD MILLION)
    FIGURE 16 MARKET, BY MODE OF PURCHASE, 2021 VS. 2026 (USD MILLION)
    FIGURE 17 GEOGRAPHIC SNAPSHOT: PEN NEEDLES INDUSTRY

4 PREMIUM INSIGHTS (Page No. - 49)
    4.1 MARKET OVERVIEW
           FIGURE 18 GROWING PREVALENCE OF CHRONIC DISEASES TO DRIVE THE GROWTH OF THE MARKET
    4.2 ASIA PACIFIC: MARKET, BY THERAPY AND COUNTRY
           FIGURE 19 JAPAN DOMINATES THE APAC MARKET
    4.3 MARKET: GEOGRAPHIC MIX
           FIGURE 20 INDIA & CHINA TO WITNESS THE HIGHEST GROWTH IN THE PEN NEEDLES MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 52)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 21 PEN NEEDLES INDUSTRY: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Growing prevalence of chronic diseases
                               FIGURE 22 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN THE US, 1995–2030 (MILLION INDIVIDUALS)
                               FIGURE 23 ESTIMATED DIABETIC POPULATION, BY REGION, 2019 VS. 2030 VS. 2040
                    5.2.1.2 Favorable reimbursement in select countries
           5.2.2 RESTRAINTS
                    5.2.2.1 Preference for alternative modes of drug delivery
                    5.2.2.2 Poor reimbursement scenario in developing countries
                    5.2.2.3 Needle anxiety
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growing preference for biosimilar drugs
                    5.2.3.2 Emerging markets
                               TABLE 2 RISING INCOME LEVELS IN EMERGING COUNTRIES
           5.2.4 CHALLENGES
                    5.2.4.1 Reuse of pen needles
                    5.2.4.2 Misuse of injection pens
    5.3 PRICING ANALYSIS
           TABLE 3 PRICING OF PEN NEEDLES AVAILABLE IN THE MARKET
    5.4 VALUE CHAIN ANALYSIS
           FIGURE 24 MARKET: VALUE CHAIN ANALYSIS
    5.5 ECOSYSTEM MARKET MAP
           FIGURE 25 MARKET: ECOSYSTEM MARKET MAP
    5.6 PORTER’S FIVE FORCES ANALYSIS
           TABLE 4 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.6.1 INTENSITY OF COMPETITIVE RIVALRY
           5.6.2 BARGAINING POWER OF SUPPLIERS
           5.6.3 BARGAINING POWER OF BUYERS
           5.6.4 THREAT OF SUBSTITUTES
           5.6.5 THREAT OF NEW ENTRANTS
    5.7 SUPPLY CHAIN ANALYSIS
           FIGURE 26 MARKET: SUPPLY CHAIN ANALYSIS
    5.8 REGULATORY ANALYSIS
           5.8.1 NORTH AMERICA
                    5.8.1.1 US
                               TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION
                               TABLE 6 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
                    5.8.1.2 Canada
                               TABLE 7 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
                               FIGURE 27 CANADA: CLASS II MEDICAL DEVICE APPROVAL PROCESS
           5.8.2 EUROPE
                    FIGURE 28 EUROPE: CE APPROVAL PROCESS FOR CLASS IIA MEDICAL DEVICES
           5.8.3 ASIA PACIFIC
                    5.8.3.1 Japan
                               TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
                    5.8.3.2 China
                               TABLE 9 CHINA: REGULATORY BODIES APPOINTED FOR MEDICAL DEVICE APPROVAL
                               TABLE 10 CHINA: CLASSIFICATION OF MEDICAL DEVICES
                    5.8.3.3 India
    5.9 IMPACT OF COVID-19 ON THE MARKET
    5.10 PATENT ANALYSIS
           5.10.1 PATENT PUBLICATION TRENDS FOR PEN NEEDLES
                     FIGURE 29 PATENT PUBLICATION TRENDS (2011–MAY 2021)
           5.10.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
                     FIGURE 30 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR PEN NEEDLES PATENTS (JANUARY 2011–JUNE 2021)
                     FIGURE 31 TOP APPLICANT COUNTRIES/REGIONS FOR PEN NEEDLE PATENTS (JANUARY 2011–JUNE 2021)
    5.11 TECHNOLOGY ANALYSIS
           5.11.1 KEY TECHNOLOGY
                    5.11.1.1 Fluid flow enhancement technology
           5.11.2 COMPLEMENTARY TECHNOLOGY
                    5.11.2.1 Microfabricated needles
           5.11.3 ADJACENT TECHNOLOGY
                    5.11.3.1 Autoinjectors

6 PEN NEEDLES MARKET, BY TYPE (Page No. - 73)
    6.1 INTRODUCTION
           TABLE 11 PEN NEEDLES INDUSTRY, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 12 MARKET, BY TYPE, 2019–2026 (MILLION UNITS)
    6.2 STANDARD PEN NEEDLES
           6.2.1 STANDARD PEN NEEDLES ARE PREFERRED OVER SAFETY PEN NEEDLES AS THEY ARE MORE AFFORDABLE
                    TABLE 13 STANDARD PEN NEEDLES OFFERED BY KEY PLAYERS
                    TABLE 14 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 15 MARKET, BY COUNTRY, 2019–2026 (MILLION UNITS)
    6.3 SAFETY PEN NEEDLES
           6.3.1 GROWING CONCERN OVER NEEDLESTICK INJURIES DRIVES THE GROWTH OF SAFETY PEN NEEDLES
                    TABLE 16 SAFETY PEN NEEDLES OFFERED BY KEY PLAYERS
                    TABLE 17 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 18 MARKET, BY COUNTRY, 2019–2026 (MILLION UNITS)

7 PEN NEEDLES MARKET, BY LENGTH (Page No. - 80)
    7.1 INTRODUCTION
           TABLE 19 PEN NEEDLES INDUSTRY, BY LENGTH, 2019–2026 (USD MILLION)
    7.2 8MM PEN NEEDLES
           7.2.1 8MM PEN NEEDLES WILL CONTINUE TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
                    TABLE 20 8MM PEN NEEDLES OFFERED BY KEY PLAYERS
                    TABLE 21 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.3 5MM PEN NEEDLES
           7.3.1 5MM PEN NEEDLES TO REGISTER SECOND-HIGHEST GROWTH RATE DURING THE STUDY PERIOD
                    TABLE 22 5MM PEN NEEDLES OFFERED BY KEY PLAYERS
                    TABLE 23 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.4 6MM PEN NEEDLES
           7.4.1 6MM PEN NEEDLES ARE THE MOST COMMONLY USED NEEDLES ACROSS THE GLOBE
                    TABLE 24 6MM PEN NEEDLES OFFERED BY KEY PLAYERS
                    TABLE 25 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.5 4MM PEN NEEDLES
           7.5.1 4MM PEN NEEDLES ARE EXPECTED TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
                    TABLE 26 4MM PEN NEEDLES OFFERED BY KEY PLAYERS
                    TABLE 27 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.6 12MM PEN NEEDLES
           7.6.1 THE POPULARITY OF SHORTER & LESS PAINFUL NEEDLES HAMPERS THE GROWTH OF THE MARKET
                    TABLE 28 12MM PEN NEEDLES OFFERED BY KEY PLAYERS
                    TABLE 29 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.7 10MM PEN NEEDLES
           7.7.1 AVAILABILITY OF SHORTER PEN NEEDLES TO RESTRAIN THE GROWTH OF THE MARKET
                    TABLE 30 10MM PEN NEEDLES OFFERED BY KEY PLAYERS
                    TABLE 31 MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

8 PEN NEEDLES MARKET, BY THERAPY (Page No. - 91)
    8.1 INTRODUCTION
           TABLE 32 PEN NEEDLES INDUSTRY, BY THERAPY, 2019–2026 (USD MILLION)
    8.2 INSULIN THERAPY
           8.2.1 RISING PREVALENCE OF DIABETES DRIVES THE GROWTH OF THE MARKET FOR INSULIN THERAPY
                    TABLE 33 MARKET FOR INSULIN THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)
    8.3 GLUCAGON-LIKE PEPTIDE-1 THERAPY
           8.3.1 STRONG FOCUS OF MAJOR PHARMACEUTICAL COMPANIES TO INTRODUCE GLP-1 DRUGS TO DRIVE MARKET GROWTH
                    TABLE 34 MARKET FOR GLP-1 THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)
    8.4 GROWTH HORMONE THERAPY
           8.4.1 DEVELOPMENT OF SUSTAINED-RELEASE GROWTH HORMONE FORMULATIONS FOR REDUCING INJECTION FREQUENCY TO RESTRAIN THE GROWTH OF THE MARKET FOR GROWTH HORMONE THERAPY
                    TABLE 35 MARKET FOR GROWTH HORMONE THERAPY, BY COUNTRY, 2019–2026 (USD MILLION)
    8.5 OTHER THERAPIES
           TABLE 36 MARKET FOR OTHER THERAPIES, BY COUNTRY, 2019–2026 (USD MILLION)

9 PEN NEEDLES MARKET, BY MODE OF PURCHASE (Page No. - 98)
    9.1 INTRODUCTION
           TABLE 37 PEN NEEDLES INDUSTRY, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
    9.2 RETAIL
           9.2.1 RETAIL PURCHASES OF PEN NEEDLES TO WITNESS HIGH GROWTH IN THE COMING YEARS OWING TO THE GROWING POPULARITY OF ONLINE PURCHASES
                    TABLE 38 MARKET FOR RETAIL PURCHASES, BY COUNTRY, 2019–2026 (USD MILLION)
    9.3 NON-RETAIL
           9.3.1 LARGE NUMBER OF NEEDLE-PHOBIC DIABETIC PATIENTS IS SUPPORTING THE GROWTH OF THIS SEGMENT
                    TABLE 39 INDICATIVE LIST OF REGULATIONS
                    TABLE 40 MARKET FOR NON-RETAIL PURCHASES, BY COUNTRY, 2019–2026 (USD MILLION)

10 PEN NEEDLES MARKET, BY REGION (Page No. - 103)
     10.1 INTRODUCTION
             TABLE 41 PEN NEEDLES INDUSTRY, BY REGION, 2019–2026 (USD MILLION)
             FIGURE 32 EMERGING COUNTRIES ARE EXPECTED TO WITNESS HIGHER GROWTH OVER THE FORECAST PERIOD
     10.2 NORTH AMERICA
             FIGURE 33 NORTH AMERICA: PEN NEEDLES MARKET SNAPSHOT
             TABLE 42 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 43 NORTH AMERICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 44 NORTH AMERICA: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
             TABLE 45 NORTH AMERICA: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
             TABLE 46 NORTH AMERICA: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
             10.2.1 US
                        10.2.1.1 The US dominates the global pen needles industry
                                     FIGURE 34 TOTAL FERTILITY RATE IN THE US POPULATION (1990-2020)
                                     TABLE 47 US: KEY MACROINDICATORS
                                     TABLE 48 US: PEN NEEDLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 49 US: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
                                     TABLE 50 US: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 51 US: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Unfavorable regulatory processes in Canada to restrain the market growth
                                     TABLE 52 CANADA: KEY MACROINDICATORS
                                     TABLE 53 CANADA: PEN NEEDLES INDUSTRY, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 54 CANADA: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
                                     TABLE 55 CANADA: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 56 CANADA: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
     10.3 EUROPE
             TABLE 57 EUROPE: PEN NEEDLES INDUSTRY, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 58 EUROPE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 59 EUROPE: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
             TABLE 60 EUROPE: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
             TABLE 61 EUROPE: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 High diabetes expenditure and reimbursement for pen needles is expected to drive the market in Germany
                                     TABLE 62 GERMANY: KEY MACROINDICATORS
                                     TABLE 63 GERMANY: PEN NEEDLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 64 GERMANY: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
                                     TABLE 65 GERMANY: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 66 GERMANY: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
             10.3.2 FRANCE
                        10.3.2.1 Favorable health insurance system to drive the pen needles industry in France
                                     TABLE 67 FRANCE: KEY MACROINDICATORS
                                     TABLE 68 FRANCE: PEN NEEDLES INDUSTRY, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 69 FRANCE: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
                                     TABLE 70 FRANCE: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 71 FRANCE: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION) 2019–2026 (USD MILLION) 120
             10.3.3 UK
                        10.3.3.1 NHS support and access to cost-effective pen needles are likely to drive the market in the UK
                                     TABLE 72 UK: KEY MACROINDICATORS
                                     TABLE 73 UK: PEN NEEDLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 74 UK: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
                                     TABLE 75 UK: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 76 UK: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
             10.3.4 ITALY
                        10.3.4.1 Regional variation in terms of coverage and benefits to hinder the market growth
                                     TABLE 77 ITALY: KEY MACROINDICATORS
                                     TABLE 78 ITALY: PEN NEEDLES INDUSTRY, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 79 ITALY: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
                                     TABLE 80 ITALY: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 81 ITALY: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 Supportive regulations mandating the use of safety pen needles to boost the growth of the Spanish market
                                     TABLE 82 SPAIN: KEY MACROINDICATORS
                                     TABLE 83 SPAIN: PEN NEEDLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 84 SPAIN: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
                                     TABLE 85 SPAIN: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 86 SPAIN: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
             10.3.6 REST OF EUROPE
                        TABLE 87 ROE: PEN NEEDLES INDUSTRY, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 88 ROE: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
                        TABLE 89 ROE: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                        TABLE 90 ROE: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
     10.4 ASIA PACIFIC
             FIGURE 35 APAC: PEN NEEDLES MARKET SNAPSHOT
             TABLE 91 APAC: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 92 APAC: MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 93 APAC: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
             TABLE 94 APAC: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
             TABLE 95 APAC: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
             10.4.1 JAPAN
                        10.4.1.1 High diabetes incidence and supportive reimbursement policies to drive the market growth in Japan
                                     TABLE 96 JAPAN: KEY MACROINDICATORS
                                     TABLE 97 JAPAN: PEN NEEDLES INDUSTRY, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 98 JAPAN: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
                                     TABLE 99 JAPAN: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 100 JAPAN: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
             10.4.2 CHINA
                        10.4.2.1 Large patient population and healthcare infrastructure improvements to drive the market growth in China
                                     TABLE 101 CHINA: KEY MACROINDICATORS
                                     TABLE 102 CHINA: PEN NEEDLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 103 CHINA: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
                                     TABLE 104 CHINA: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 105 CHINA: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
             10.4.3 AUSTRALIA AND NEW ZEALAND
                        10.4.3.1 Growing geriatric population in Australia and New Zealand to drive the pen needles market
                                     TABLE 106 AUSTRALIA AND NEW ZEALAND: PEN NEEDLES INDUSTRY, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 107 AUSTRALIA AND NEW ZEALAND: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
                                     TABLE 108 AUSTRALIA AND NEW ZEALAND: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 109 AUSTRALIA AND NEW ZEALAND: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
             10.4.4 INDIA
                        10.4.4.1 Healthcare infrastructural improvements and implementation of favorable government initiatives support the market in India
                                     TABLE 110 INDIA: KEY MACROINDICATORS
                                     TABLE 111 INDIA: PEN NEEDLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 112 INDIA: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
                                     TABLE 113 INDIA: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 114 INDIA: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
             10.4.5 SOUTH KOREA
                        10.4.5.1 Growing chronic diseases in the geriatric population augments the growth of the pen needles market
                                     TABLE 115 SOUTH KOREA: PEN NEEDLES INDUSTRY, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 116 SOUTH KOREA: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
                                     TABLE 117 SOUTH KOREA: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 118 SOUTH KOREA: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
             10.4.6 SOUTHEAST ASIA
                        10.4.6.1 Growing awareness about diabetes drives the pen needles market
                                     FIGURE 36 GROWING PREVALENCE OF DIABETES IN SOUTHEAST ASIA
                                     FIGURE 37 HEALTHCARE EXPENDITURE (% GDP) IN SOUTHEAST ASIA (2018)
                                     FIGURE 38 GERIATRIC POPULATION IN 2019 (% OF TOTAL POPULATION)
                                     TABLE 119 SOUTHEAST ASIA: PEN NEEDLES INDUSTRY, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 120 SOUTHEAST ASIA: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
                                     TABLE 121 SOUTHEAST ASIA: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 122 SOUTHEAST ASIA: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
             10.4.7 REST OF APAC
                        TABLE 123 ROAPAC: PEN NEEDLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 124 ROAPAC: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
                        TABLE 125 ROAPAC: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                        TABLE 126 ROAPAC: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
     10.5 LATIN AMERICA
             TABLE 127 LATIN AMERICA: PEN NEEDLES INDUSTRY, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 128 LATIN AMERICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 129 LATIN AMERICA: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
             TABLE 130 LATIN AMERICA: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
             TABLE 131 LATIN AMERICA: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
             10.5.1 BRAZIL
                        10.5.1.1 Brazil dominates the pen needles market in Latin America
                                     TABLE 132 BRAZIL: KEY MACROINDICATORS
                                     TABLE 133 BRAZIL: PEN NEEDLES INDUSTRY, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 134 BRAZIL: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
                                     TABLE 135 BRAZIL: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 136 BRAZIL: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
             10.5.2 MEXICO
                        10.5.2.1 Increasing incidence of lifestyle-related disorders and rising awareness drive market growth in Mexico
                                     TABLE 137 MEXICO: KEY MACROINDICATORS
                                     TABLE 138 MEXICO: PEN NEEDLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 139 MEXICO: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
                                     TABLE 140 MEXICO: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 141 MEXICO: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
             10.5.3 REST OF LATIN AMERICA
                        FIGURE 39 HEALTH EXPENDITURE IN LATIN AMERICAN COUNTRIES IN 2018 (% GDP)
                        TABLE 142 ROLA: PEN NEEDLES INDUSTRY, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 143 ROLA: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
                        TABLE 144 ROLA: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                        TABLE 145 ROLA: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)
     10.6 MIDDLE EAST AND AFRICA
             10.6.1 INITIATIVES TO ENHANCE HEALTHCARE ACCESSIBILITY MAY SUPPORT MARKET GROWTH
                        TABLE 146 MEA: PEN NEEDLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 147 MEA: MARKET, BY LENGTH, 2019–2026 (USD MILLION)
                        TABLE 148 MEA: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                        TABLE 149 MEA: MARKET, BY MODE OF PURCHASE, 2019–2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 155)
     11.1 OVERVIEW
     11.2 KEY PLAYER STRATEGIES
     11.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
             FIGURE 40 REVENUE ANALYSIS OF THE TOP PLAYERS IN THE PEN NEEDLES MARKET
     11.4 PEN NEEDLES INDUSTRY SHARE ANALYSIS
             FIGURE 41 MARKET SHARE, BY KEY PLAYER, 2020
     11.5 COMPANY EVALUATION QUADRANT
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 42 MARKET: COMPANY EVALUATION QUADRANT (2020)
     11.6 COMPANY EVALUATION QUADRANT FOR START-UPS
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 DYNAMIC COMPANIES
             11.6.3 STARTING BLOCKS
             11.6.4 RESPONSIVE COMPANIES
                        FIGURE 43 MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS (2020)
     11.7 COMPANY PRODUCT FOOTPRINT
             TABLE 150 PRODUCT PORTFOLIO ANALYSIS: PEN NEEDLES INDUSTRY
             TABLE 151 PRODUCT PORTFOLIO ANALYSIS: PEN NEEDLES INDUSTRY, BY LENGTH
             TABLE 152 PRODUCT PORTFOLIO ANALYSIS: PEN NEEDLES INDUSTRY, BY THERAPY
     11.8 COMPANY GEOGRAPHIC FOOTPRINT
             TABLE 153 GEOGRAPHIC REVENUE MIX: PEN NEEDLES INDUSTRY (2020)
     11.9 COMPETITIVE INTENSITY
             11.9.1 EVALUATION PARAMETERS
                        TABLE 154 EVALUATION PARAMETERS & SCORES
             11.9.2 SCORING METHODOLOGY FOR COMPETITIVE INTENSITY
                        FIGURE 44 SCORING METHODOLOGY FOR COMPETITIVE INTENSITY
             11.9.3 COMPETITIVE INTENSITY SCORE, BY COMPANY
                        11.9.3.1 Competitive intensity score for BD
                                     TABLE 155 COMPETITIVE INTENSITY FOR BD
                        11.9.3.2 Competitive intensity score for Novo Nordisk
                                     TABLE 156 COMPETITIVE INTENSITY FOR NOVO NORDISK
                        11.9.3.3 Competitive intensity score for Ypsomed
                                     TABLE 157 COMPETITIVE INTENSITY FOR YPSOMED
             11.9.4 COMPETITIVE INTENSITY MAPPING: BD, NOVO NORDISK, AND YPSOMED
                                     FIGURE 45 COMPARISONS OF COMPETITIVE INTENSITY SCORES: BD, NOVO NORDISK, AND YPSOMED
                                     FIGURE 46 RELATIVE POSITIONING OF COMPANIES BASED ON COMPETITIVE INTENSITY SCORE AND PEN NEEDLE FOCUS
                        11.9.4.1 Product launches/technological advancements
                                     FIGURE 47 BD HAS A HIGHER FOCUS ON INNOVATION FOR ITS PEN NEEDLES BUSINESS
                        11.9.4.2 Promotional/marketing activities
                                     FIGURE 48 BD AND NOVO NORDISK SHOWCASE A HIGH FOCUS ON MARKETING & PROMOTIONAL ACTIVITIES
                        11.9.4.3 Sponsorships/donations/education/awareness campaigns
                                     FIGURE 49 NOVO NORDISK A/S HAS A HIGH FOCUS ON DIABETES EDUCATION & AWARENESS
                        11.9.4.4 Certifications/accreditations/awards
                                     FIGURE 50 BD, NOVO NORDISK, AND YPSOMED EQUALLY EXHIBIT HIGH COMPLIANCE WITH INDUSTRY STANDARDS
     11.1 COMPETITIVE SCENARIO
             11.10.1 PRODUCT LAUNCHES
                        TABLE 158 PRODUCT LAUNCHES (JANUARY 2018 – JUNE 2021)
             11.10.2 DEALS
                        TABLE 159 DEALS (JANUARY 2018– JUNE 2021)
             11.10.3 OTHER DEVELOPMENTS
                        TABLE 160 OTHER DEVELOPMENTS (JANUARY 2018– JUNE 2021)

12 COMPANY PROFILES (Page No. - 177)
     12.1 KEY PLAYERS
(Business overview, Products offered, Recent developments, MNM view)*
             12.1.1 BECTON, DICKINSON AND COMPANY
                        TABLE 161 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 51 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
             12.1.2 NOVO NORDISK A/S
                        TABLE 162 NOVO NORDISK A/S: BUSINESS OVERVIEW
                        FIGURE 52 NOVO NORDISK A/S: COMPANY SNAPSHOT (2020)
             12.1.3 YPSOMED HOLDING AG
                        TABLE 163 YPSOMED HOLDING AG: BUSINESS OVERVIEW
                        FIGURE 53 YPSOMED HOLDING AG: COMPANY SNAPSHOT (2020)
             12.1.4 B. BRAUN MELSUNGEN AG
                        TABLE 164 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
                        FIGURE 54 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2020)
             12.1.5 TERUMO CORPORATION
                        TABLE 165 TERUMO CORPORATION: BUSINESS OVERVIEW
                        FIGURE 55 TERUMO CORPORATION: COMPANY SNAPSHOT (2020)
             12.1.6 NIPRO CORPORATION
                        TABLE 166 NIPRO CORPORATION: BUSINESS OVERVIEW
                        FIGURE 56 NIPRO CORPORATION: COMPANY SNAPSHOT (2020)
             12.1.7 OWEN MUMFORD
                        TABLE 167 OWEN MUMFORD: BUSINESS OVERVIEW
             12.1.8 ARKRAY
                        TABLE 168 ARKRAY: BUSINESS OVERVIEW
             12.1.9 ULTIMED
                        TABLE 169 ULTIMED: BUSINESS OVERVIEW
             12.1.10 HINDUSTAN SYRINGES AND MEDICAL DEVICES
                        TABLE 170 HINDUSTAN SYRINGES AND MEDICAL DEVICES: BUSINESS OVERVIEW
             12.1.11 MONTMED
                        TABLE 171 MONTMED: BUSINESS OVERVIEW
             12.1.12 HTL-STREFA
                        TABLE 172 HTL-STREFA: BUSINESS OVERVIEW
             12.1.13 ALLISON MEDICAL, INC.
                        TABLE 173 ALLISON MEDICAL: BUSINESS OVERVIEW
             12.1.14 GLUCORX
                        TABLE 174 GLUCORX: BUSINESS OVERVIEW
             12.1.15 BERPU MEDICAL TECHNOLOGY
                        TABLE 175 BERPU MEDICAL TECHNOLOGY: BUSINESS OVERVIEW
             12.1.16 ADVACARE PHARMA
                        TABLE 176 ADVACARE PHARMA: BUSINESS OVERVIEW
             12.1.17 ARTSANA GROUP
                        TABLE 177 ARTSANA GROUP: BUSINESS OVERVIEW
             12.1.18 PROMISEMED DIABETES CARE
                        TABLE 178 PROMISEMED DIABETES CARE: BUSINESS OVERVIEW
             12.1.19 TRIVIDIA HEALTH
                        TABLE 179 TRIVIDIA HEALTH: BUSINESS OVERVIEW
             12.1.20 VOGT MEDICAL VERTRIEB
                        TABLE 180 VOGT MEDICAL VERTRIEB GMBH: BUSINESS OVERVIEW
*Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.
     12.2 OTHER PLAYERS
             12.2.1 VAN HEEK MEDICAL
                        TABLE 181 VAN HEEK MEDICAL: COMPANY OVERVIEW
             12.2.2 SIMPLE DIAGNOSTICS
                        TABLE 182 SIMPLE DIAGNOSTICS: COMPANY OVERVIEW
             12.2.3 IYON
                        TABLE 183 IYON: COMPANY OVERVIEW
             12.2.4 LINKS MEDICAL PRODUCTS
                        TABLE 184 LINKS MEDICAL PRODUCTS: COMPANY OVERVIEW
             12.2.5 MHC MEDICAL PRODUCTS
                        TABLE 185 MHC MEDICAL PRODUCTS: COMPANY OVERVIEW

13 APPENDIX (Page No. - 216)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources; directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the pen needles market. It was also used to obtain important information about the key players, market classification and segmentation according to industry trends to the bottommost level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side and demand side are detailed below.

A breakdown of the primary respondents is provided below:

Pen Needles Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the pen needles market was arrived at after data triangulation from four different approaches, as mentioned below. After each approach, the weighted average of all approaches was taken based on the level of assumptions used in each approach.

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The following figure shows the market validation, source structure, and data triangulation methodology implemented in this report’s market engineering process.

Objectives of the Study

To validate the segmentation defined through the assessment of the product portfolios of the leading players in the market
To understand key industry trends and issues defining the growth objectives of market players
To gather both demand- and supply-side validation of the key factors affecting market growth, including market drivers, restraints, opportunities, and challenges
To validate assumptions for the market sizing and forecasting model used for this market study
To understand the market positions of the leading players in the pen needles market and their shares/rankings
To understand the ongoing pricing trends in the market and future expectations

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Geographic Analysis

Further breakdown of the RoE pen needles market into Belgium, Russia, the Netherlands, Switzerland, and others.
Further breakdown of the RoAPAC pen needles market into Pakistan, Myanmar, Bangladesh and Cambodia.
Further breakdown of the RoLA pen needles market into Argentina, Chile, Peru, Ecuador, Colombia, Uruguay, Bolivia, and Venezuela.

Portfolio Assessment

Product Matrix, which gives a detailed comparison of the product portfolios of the top three companies

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.